Philip has spent more than 30 years in the pharmaceutical industry undertaking a variety of roles in clinical development, regulatory affairs and project management.
At GlaxoWellcome plc, he oversaw the clinical development of several small molecules and monoclonal antibodies for the treatment of cancer. As Head of Clinical Operations and Regulatory Affairs at Acambis plc, he was involved in the successful licensure of a second generation smallpox vaccine as part of the US Department of Defense biosecurity initiative and also the early stage development of what subsequently became the World’s first licensed vaccine for Dengue fever. Over the last 10 years he has been providing independent clinical development and regulatory advice to blue chip pharma and biotechnology companies, with a particular focus on vaccines and other biologics.
Philip is a member of Cambridge East Research Ethics Committee and mentors students at the University of Manchester.